Search results

  1. Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation (TA429)

    Evidence-based recommendations on ibrutinib (Imbruvica) for treating chronic lymphocytic leukaemia in adults

  2. Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (TA426)

    Evidence-based recommendations on dasatinib (Sprycel), nilotinib (Tasigna) and imatinib (Glivec) for untreated chronic myeloid leukaemia in adults

  3. Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (TA425)

    Evidence-based recommendations on dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant/intolerant chronic myeloid leukaemia in adults

  4. Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)

    Evidence-based recommendations on pertuzumab (Perjeta) for treating HER2-positive breast cancer that is locally advanced, inflammatory, or early-stage with a

  5. Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (TA423)

    Evidence-based recommendations on eribulin (Halaven) for treating locally advanced or metastatic breast cancer after 2 or more types of chemotherapy

  6. Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA422)

    Evidence-based recommendations on crizotinib (Xalkori) for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults

  7. Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421)

    Evidence-based recommendations on everolimus (Afinitor) for treating advanced breast cancer in adults after endocrine therapy

  8. Ticagrelor for preventing atherothrombotic events after myocardial infarction (TA420)

    Evidence-based recommendations on ticagrelor (Brilique) for preventing atherothrombotic events such as heart attacks or stroke after myocardial infarction (MI)

  9. Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor (TA415)

    Evidence-based recommendations on certolizumab pegol (Cimzia) for treating severe active rheumatoid arthritis in adults who have had a tumour necrosis factor

  10. Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA414)

    Evidence-based recommendations on cobimetinib (Cotellic) with vemurafenib (Zelboraf) for unresectable or metastatic melanoma in adults with a BRAF V600

  11. Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412)

    Evidence-based recommendations on radium-223 dichloride (Xofigo) for treating hormone-relapsed prostate cancer with bone metastases

  12. Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer (TA411)

    Evidence-based recommendations on necitumumab (Portrazza) for untreated advanced or metastatic squamous non-small-cell lung cancer (NSCLC) in adults

  13. Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion (TA409)

    Evidence-based recommendations on aflibercept (Eylea) for treating visual impairment caused by macular oedema after branch retinal vein occlusion

  14. Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors (TA407)

    Evidence-based recommendations on secukinumab (Cosentyx) for ankylosing spondylitis (spondyloartritis) that has not responded well enough to conventional

  15. Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA406)

    Evidence-based recommendations on crizotinib (Xalkori) for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (NSCLC) in adults

  16. Degarelix for treating advanced hormone-dependent prostate cancer (TA404)

    Evidence-based recommendations on degarelix (Firmagon) for advanced hormone-dependent prostate cancer in adults with spinal metastases